商务合作
动脉网APP
可切换为仅中文
Nearly 40% of patients alive at three years with
三年后存活的患者中近40%
Ziihera
齐赫拉
plus tislelizumab and chemotherapy, irrespective of PD-L1 status, achieving a median OS of 27 months
联合替雷利珠单抗和化疗,无论PD-L1状态如何,中位总生存期达到27个月
Mature HERIZON-GEA-01 results show
HERIZON-GEA-01 的成熟结果显示
Ziihera
齐赫拉
plus chemotherapy delivered statistically significant and clinically meaningful OS benefit, reducing the risk of death by 24% versus trastuzumab plus chemotherapy
与曲妥珠单抗联合化疗相比,加用该药物可带来具有统计学显著性和临床意义的总生存期(OS)获益,将死亡风险降低24%。
For U.S. media and investors only
仅限美国媒体和投资者
DUBLIN
都柏林
,
,
Oct. 23, 2026
2026年10月23日
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq:
/美通社/ -- Jazz Pharmaceuticals plc(纳斯达克:
JAZZ
爵士乐
) today announced updated overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera
)今日公布了评估Ziihera的III期HERIZON-GEA-01试验的最新总生存期(OS)结果
®
®
(zanidatamab-hrii) in combination with chemotherapy, with or without Tevimbra
(zanidatamab-hrii)联合化疗,伴或不伴替维普利单抗
®
®
(tislelizumab-jsgr), as first-line treatment for adults with HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results from the second interim, and final formal, analysis were presented as a late-breaking rapid oral presentation (LBA79) at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain..
(替雷利珠单抗-jsgr)作为HER2阳性(HER2+)局部晚期或转移性胃食管腺癌(GEA)成人患者的一线治疗方案。第二次中期分析及最终正式分析的结果在西班牙马德里举行的2026年欧洲肿瘤内科学会(ESMO)大会上以最新突破性快速口头报告(LBA79)的形式公布。
'For patients with HER2+ advanced GEA, long-term survival remains difficult to achieve. With longer follow-up,
对于HER2阳性晚期胃食管腺癌(GEA)患者,长期生存仍难以实现。随着随访时间的延长,
Ziihera
齐赫拉
-containing regimens demonstrated a durable overall survival benefit, with nearly 40% of patients treated with
含……的方案显示出持久的总生存期获益,近40%接受……治疗的患者
Ziihera
齐赫拉
plus tislelizumab and chemotherapy alive at three years,' said Dr. Kohei Shitara, director of the Department of Gastrointestinal Oncology, and principal trial investigator at the National Cancer Center Hospital East, Kashiwa, Japan. '
“加上替雷利珠单抗和化疗,三年生存率更高,”日本柏市国立癌症中心东医院胃肠肿瘤科主任兼主要试验研究者Kohei Shitara博士表示。
Ziihera
齐赫拉
plus chemotherapy has also now demonstrated a statistically significant survival benefit over trastuzumab plus chemotherapy. Together, these findings provide strong evidence for
加化疗也已显示出相较于曲妥珠单抗加化疗具有统计学显著的生存获益。这些发现共同为
Ziihera
齐赫拉
-containing regimens as the new HER2-directed first-line standard of care.'
含该药物的方案作为新的HER2靶向一线标准治疗。
At the data cutoff, median follow-up was 35.3 months, 9.4 months longer than at the first interim analysis. Key findings included:
在数据截止时,中位随访时间为35.3个月,较首次中期分析时延长了9.4个月。主要发现包括:
Ziihera
齐赫拉
plus tislelizumab and chemotherapy sustained its OS benefit versus trastuzumab plus chemotherapy, with an improved HR:
替雷利珠单抗联合化疗相较于曲妥珠单抗联合化疗,其总生存期(OS)获益得以维持,且风险比(HR)改善:
Median OS reached 27.0 months (95% confidence interval [CI]: 23.7-32.2), the longest reported in a Phase 3 trial in this setting, compared with 19.6 months with trastuzumab plus chemotherapy. The
中位总生存期(OS)达到27.0个月(95%置信区间[CI]:23.7-32.2),是该适应症下III期临床试验中报道的最长结果,而曲妥珠单抗联合化疗组为19.6个月。
Ziihera
齐赫拉
plus tislelizumab and chemotherapy regimen reduced the risk of death by 35% (hazard ratio [HR] 0.65; 95% CI: 0.52-0.80), improving from an HR of 0.72 at the first interim analysis.
替雷利珠单抗联合化疗方案将死亡风险降低了35%(风险比[HR] 0.65;95% CI:0.52-0.80),较首次中期分析时的HR 0.72有所改善。
Nearly 40% of patients receiving
近40%的接受治疗的病人
Ziihera
齐赫拉
plus tislelizumab and chemotherapy were alive at three years:
加用替雷利珠单抗和化疗的患者在三年时仍存活:
Estimated 36-month OS was 39.8% with
预计36个月总生存率为39.8%,
Ziihera
齐赫拉
plus tislelizumab and chemotherapy, 31.5% with
加替雷利珠单抗和化疗,31.5% 伴有
Ziihera
齐赫拉
plus chemotherapy and 22.9% with trastuzumab plus chemotherapy.
加化疗,22.9% 使用曲妥珠单抗加化疗。
Ziihera
齐赫拉
plus chemotherapy demonstrated a statistically significant and clinically meaningful OS improvement versus trastuzumab plus chemotherapy:
与曲妥珠单抗联合化疗相比,加用化疗显示出统计学显著且具有临床意义的总生存期(OS)改善:
Median OS was 22.9 months (95% CI: 19.9-27.6) with
中位总生存期(OS)为22.9个月(95%置信区间:19.9-27.6),
Ziihera
齐赫拉
plus chemotherapy compared with 19.6 months (95% CI: 16.9-22.2) with trastuzumab plus chemotherapy.
加化疗相比,曲妥珠单抗加化疗的中位生存期为19.6个月(95%置信区间:16.9-22.2)。
Ziihera
齐赫拉
plus chemotherapy reduced the risk of death by 24% (HR 0.76; 95% CI: 0.62-0.93; P=0.0088).
加用化疗使死亡风险降低了24%(HR 0.76;95% CI:0.62-0.93;P=0.0088)。
Ziihera
齐赫拉
plus tislelizumab and chemotherapy showed a meaningful trend toward improved OS versus
替雷利珠单抗联合化疗显示出改善总生存期的有意义趋势,相较于
Ziihera
齐赫拉
plus chemotherapy:
加化疗:
Median OS was approximately four months longer with
中位总生存期大约延长了四个月
Ziihera
齐赫拉
plus tislelizumab and chemotherapy than with
与替雷利珠单抗联合化疗相比
Ziihera
齐赫拉
plus chemotherapy (27.0 versus 22.9 months; HR 0.81; 95% CI: 0.65-1.00; P=0.0502). The difference did not reach statistical significance. Mean duration of treatment was longest for
加化疗(27.0 个月 vs 22.9 个月;HR 0.81;95% CI:0.65-1.00;P=0.0502)。差异未达到统计学显著性。平均治疗持续时间最长的是
Ziihera
齐赫拉
plus tislelizumab and chemotherapy (64.1 weeks): 11.5 weeks longer than
替雷利珠单抗联合化疗(64.1周):比...长11.5周
Ziihera
齐赫拉
plus chemotherapy (52.6 weeks), and 21.8 weeks longer than trastuzumab plus chemotherapy (42.3 weeks).
加化疗(52.6周),且比曲妥珠单抗加化疗(42.3周)长21.8周。
Safety profiles remained unchanged with longer follow-up:
随着随访时间的延长,安全性特征保持不变:
The safety profiles of both
两者的安全性特征
Ziihera
齐赫拉
-containing regimens were consistent with the first interim analysis, supporting the tolerability of prolonged treatment.
含……的方案与首次中期分析结果一致,支持长期治疗的良好耐受性。
'These HERIZON-GEA-01 three-year landmark results demonstrate meaningful survival outcomes for patients with HER2+ advanced GEA,' said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of R&D, and chief medical officer of Jazz Pharmaceuticals. 'The statistically significant survival benefit observed with .
“这些 HERIZON-GEA-01 研究的三年里程碑式结果证实,HER2 阳性晚期胃食管腺癌(GEA)患者获得了具有临床意义的生存获益。”Jazz Pharmaceuticals 执行副总裁、全球研发负责人兼首席医疗官 Rob Iannone 医学博士、临床流行病学硕士表示。“观察到的具有统计学显著性的生存获益……”
Ziihera
齐赫拉
plus chemotherapy and the durable outcomes seen with
加化疗以及所见的持久疗效
Ziihera
齐赫拉
plus tislelizumab and chemotherapy cement
替雷利珠单抗联合化疗
Ziihera
齐赫拉
as the new HER2-targeted backbone therapy in first-line HER2+ advanced GEA.'
作为一线HER2阳性晚期胃食管腺癌(GEA)的新一代HER2靶向基础治疗
The
这
Ziihera
齐赫拉
-containing regimens were recently included as preferred therapies in the National Comprehensive Cancer Network
含……的方案最近被纳入美国国家综合癌症网络的首选治疗方案
®
注册商标
(NCCN
(NCCN
®
®
) Clinical Practice Guidelines in Oncology
肿瘤学临床实践指南
®
注册商标
for Gastric Cancer, and Esophageal and Esophagogastric Junction Cancers, and
用于胃癌、食管癌和食管胃结合部癌,以及
Ziihera
齐赫拉
plus tislelizumab and chemotherapy is the only preferred HER2+ regimen irrespective of PD-L1 status.
替雷利珠单抗联合化疗是唯一不受PD-L1状态影响的HER2阳性首选治疗方案。
These results follow the August 25, 2026, U.S. Food and Drug Administration (FDA)
这些结果紧随2026年8月25日美国食品药品监督管理局(FDA)
approval
批准
of two
两个的
Ziihera
齐赫拉
-containing regimens for the first-line treatment of adults with HER2+ unresectable locally advanced or metastatic GEA:
用于HER2阳性不可切除局部晚期或转移性胃食管腺癌(GEA)成人患者一线治疗的含药方案:
Ziihera
齐赫拉
plus tislelizumab and fluoropyrimidine- and platinum-containing chemotherapy for adults with HER2+ IHC 3+ or IHC 2+/ISH+ disease; and
联合替雷利珠单抗以及含氟嘧啶和铂类的化疗方案,用于患有HER2阳性(IHC 3+或IHC 2+/ISH+)疾病的成年患者;以及
Ziihera
齐赫拉
plus fluoropyrimidine- and platinum-containing chemotherapy for adults with HER2+ IHC 3+ disease. The approval was based on results from the Phase 3 HERIZON-GEA-01 trial, which were first presented at
加用含氟嘧啶和铂类的化疗方案,用于患有HER2阳性(IHC 3+)疾病的成年患者。该批准基于III期HERIZON-GEA-01试验的结果,该结果首次发表于
ASCO GI 2026
2026年ASCO胃肠道肿瘤研讨会
, subsequently published in
,随后发表于
The New England Journal of Medicine
《新英格兰医学杂志》
and further evaluated through PD-L1 subgroup analyses presented at ASCO 2026.
并通过在2026年美国临床肿瘤学会(ASCO)年会上公布的PD-L1亚组分析进一步评估。
The U.S. Prescribing Information for
美国处方信息
Ziihera
齐赫拉
contains Boxed Warnings for diarrhea and embryo-fetal toxicity.
包含关于腹泻和胚胎-胎儿毒性的黑框警告。
Additional Important Safety Information related to
与...相关的其他重要安全信息
Ziihera
齐赫拉
use in GEA is provided below. Please see full Prescription, including Boxed Warnings at
GEA 中的使用说明如下。请参阅完整处方信息,包括黑框警告,详见
https://pp.jazzpharma.com/pi/ziihera.en.USPI.pdf
https://pp.jazzpharma.com/pi/ziihera.en.USPI.pdf
.
。
About the Phase 3 HERIZON-GEA-01 Trial
关于HERIZON-GEA-01 III期临床试验
HERIZON-GEA-01 (
HERIZON-GEA-01(
NCT05152147
NCT05152147
) is a global, randomized, open-label Phase 3 trial, conducted jointly with BeOne Medicines, to evaluate and compare the efficacy and safety of zanidatamab plus chemotherapy, with and without tislelizumab, to trastuzumab plus chemotherapy as first-line treatment for adult patients with advanced/metastatic HER2+ GEA.
)是一项与百奥泰联合开展的全球性、随机、开放标签III期临床试验,旨在评估和比较zanidatamab联合化疗(伴或不伴替雷利珠单抗)与曲妥珠单抗联合化疗作为成人晚期/转移性HER2阳性胃食管腺癌(GEA)患者一线治疗的疗效和安全性。
The trial randomized 914 patients from approximately 225 trial sites in more than 30 countries. Appropriate patients for this trial had unresectable locally advanced, recurrent or metastatic HER2+ GEA (adenocarcinomas of the stomach or esophagus, including the gastroesophageal junction), defined as 3+ HER2 expression by IHC or 2+ HER2 expression by IHC with ISH positivity per central assessment.
该试验将来自30多个国家约225个试验中心的914名患者进行了随机分组。本试验的合适入组患者为不可切除的局部晚期、复发性或转移性HER2阳性胃食管腺癌(GEA,包括胃或食管腺癌,含胃食管结合部腺癌),其定义为经中心评估确认为免疫组化(IHC)HER2表达3+,或免疫组化HER2表达2+且原位杂交(ISH)检测阳性。
Patients were randomized to the three trial arms: zanidatamab in combination with chemotherapy and tislelizumab; zanidatamab in combination with chemotherapy; and trastuzumab plus chemotherapy. The trial evaluated dual primary endpoints, PFS per blinded independent central review (BICR) and OS..
患者被随机分配至三个试验组:赞尼达妥单抗联合化疗及替雷利珠单抗;赞尼达妥单抗联合化疗;以及曲妥珠单抗联合化疗。该试验评估了两个主要终点,即基于盲态独立中心审查(BICR)的无进展生存期(PFS)和总生存期(OS)。
About Gastroesophageal Adenocarcinoma
关于胃食管腺癌
GEA, including cancers of the stomach, gastroesophageal junction, and esophagus, is the fifth most common cancer worldwide, and approximately 20% of patients have HER2+ disease.
胃食管腺癌(GEA),包括胃癌、胃食管结合部癌和食管癌,是全球第五大常见癌症,约20%的患者为HER2阳性疾病。
1
1
,
,
2
2
,
,
3
3
,
,
4
4
HER2+ GEA has high morbidity and mortality, and patients are urgently in need of new treatment options. The overall prognosis for patients with GEA remains poor, with a global five-year survival rate of less than 10% for metastatic disease.
HER2阳性胃食管腺癌(GEA)具有高发病率和高死亡率,患者迫切需要使用新的治疗方案。GEA患者的总体预后仍然不佳,转移性疾病的全球五年生存率低于10%。
5
5
About Ziihera
关于Ziihera
®
®
(zanidatamab-hrii)
(赞尼达他单抗-hrii)
Ziihera
齐赫拉
(zanidatamab-hrii) is a bispecific HER2-directed antibody that binds to two extracellular sites on HER2. Binding of zanidatamab with HER2 results in internalization leading to a reduction in HER2 expression of the receptor on the tumor cell surface. Zanidatamab induces CDC, ADCC, and ADCP. These mechanisms result in tumor growth inhibition and cell death in vitro and in vivo..
(zanidatamab-hrii)是一种双特异性HER2靶向抗体,可结合HER2上的两个胞外位点。Zanidatamab与HER2结合后引发内化,导致肿瘤细胞表面HER2受体表达减少。Zanidatamab可诱导补体依赖的细胞毒性(CDC)、抗体依赖的细胞介导的细胞毒性(ADCC)和抗体依赖的细胞吞噬作用(ADCP)。这些机制在体外和体内均能抑制肿瘤生长并导致细胞死亡。
6
6
Gastroesophageal adenocarcinoma (GEA): In the United States,
胃食管腺癌(GEA):在美国,
Ziihera
齐赫拉
is indicated for the first-line treatment of adults with HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction and esophagus, in combination with tislelizumab-jsgr and fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ and IHC 2+/ISH+ as detected by an FDA-authorized test); and in combination with fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ as detected by an FDA-authorized test)..
适用于联合替雷利珠单抗-jsgr以及含氟嘧啶和铂类的化疗方案,作为HER2阳性局部晚期或转移性胃食管腺癌(GEA,包括胃癌、胃食管结合部癌和食管癌)成人患者的一线治疗(HER2阳性定义为经FDA批准的检测试剂检测为IHC 3+或IHC 2+/ISH+);以及联合含氟嘧啶和铂类的化疗方案(HER2阳性定义为经FDA批准的检测试剂检测为IHC 3+)。
Biliary tract cancer (BTC): In the United States,
胆道癌(BTC):在美国,
Ziihera
齐赫拉
is also indicated for the treatment of adults with previously treated, unresectable or metastatic HER2+ (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.
也适用于治疗经FDA批准的检测确认为HER2阳性(IHC 3+)的既往接受过治疗的不可切除或转移性胆道癌(BTC)成人患者。
6
6
Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
该适应症的持续批准可能取决于在确证性试验中对临床获益的验证和描述。
6
6
Ziihera is also approved in the European Union and other countries.
Ziihera 也在欧盟和其他国家获得批准。
Zanidatamab is being developed in multiple clinical trials as a targeted treatment option for patients with solid tumors that express HER2. Zanidatamab is being developed by Jazz and BeOne Medicines under license agreements from Zymeworks, which first developed the molecule.
Zanidatamab 正在多项临床试验中开发,作为针对表达 HER2 的实体瘤患者的靶向治疗选择。Zanidatamab 由 Jazz 公司和 BeOne Medicines 公司根据 Zymeworks 公司的许可协议进行开发,Zymeworks 是最初研发该分子的公司。
The FDA granted three Breakthrough Therapy designations for zanidatamab's development: one as a single agent for previously treated HER2 gene-amplified BTC, one in combination with fluoropyrimidine- and platinum-containing chemotherapy, with or without tislelizumab for first-line HER2+ unresectable locally advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal GEA, and one for the treatment of adults with previously treated, locally advanced, unresectable, or metastatic HER2+ colorectal cancer (CRC).
美国食品药品监督管理局(FDA)授予zanidatamab研发三项突破性疗法认定:一项用于既往接受过治疗的HER2基因扩增胆道癌(BTC)的单药治疗;一项联合含氟嘧啶和铂类的化疗方案,伴或不伴替雷利珠单抗,用于一线治疗HER2阳性不可切除局部晚期或转移性胃癌、胃食管结合部(GEJ)癌或食管胃腺癌(GEA);以及一项用于既往接受过治疗的局部晚期、不可切除或转移性HER2阳性结直肠癌(CRC)成人患者的治疗。
The FDA also granted two Fast Track designations for zanidatamab: one as a single agent for refractory BTC and one in combination with standard-of-care chemotherapy for first-line GEA. Additionally, zanidatamab has received Orphan Drug designations from the FDA for the treatment of BTC, gastric (including GEJ) cancer, and esophageal cancer, as well as Orphan Drug designations from the European Medicines Agency for the treatment of BTC, gastric/gastroesophageal junction cancer, and esophageal cancer. Jazz continues to pursue additional regulatory approvals for zanidatamab in markets worldwide..
美国食品药品监督管理局(FDA)还授予zanidatamab两项快速通道认定:一项是作为单药治疗难治性胆道癌(BTC),另一项是与标准护理化疗联合用于一线胃食管腺癌(GEA)治疗。此外,zanidatamab已获得FDA针对BTC、胃癌(包括胃食管结合部癌)和食管癌的孤儿药认定,以及欧洲药品管理局(EMA)针对BTC、胃癌/胃食管结合部癌和食管癌的孤儿药认定。Jazz公司继续在全球多个市场推进zanidatamab的额外监管审批。
Important Safety Information for ZIIHERA
ZIIHERA 的重要安全信息
WARNING: DIARRHEA and EMBRYO-FETAL TOXICITY
警告:腹泻和胚胎-胎儿毒性
ZIIHERA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, with or without
ZIIHERA 与含氟嘧啶和铂类的化疗药物联合使用,伴或不伴
tislelizumab-jsgr, can cause severe diarrhea, including life threatening and fatal cases. Use antidiarrheal
替雷利珠单抗-jsgr 可能导致严重腹泻,包括危及生命和致命的病例。使用止泻药
prophylaxis during the first cycle when ZIIHERA is given in combination with these drugs. Manage with
在ZIIHERA与这些药物联合给药的首个周期中进行预防。处理措施包括
antidiarrheals and supportive measures as clinically indicated. Interrupt, reduce the dose or discontinue
根据临床指征使用止泻药和支持治疗。中断、减量或停药
ZIIHERA based on severity.
根据严重程度使用 ZIIHERA。
Embryo-Fetal Toxicity: Exposure to ZIIHERA during pregnancy can cause embryo-fetal harm. Advise patients
胚胎-胎儿毒性:在妊娠期间接触 ZIIHERA 可能导致胚胎-胎儿损害。建议患者
of the risk and need for effective contraception.
关于风险及有效避孕的必要性。
Diarrhea:
腹泻:
ZIIHERA can cause severe diarrhea.
ZIIHERA 可能导致严重腹泻。
When ZIIHERA is used in combination with fluoropyrimidine- and platinum-containing chemotherapy with or without tislelizumab-jsgr, severe, life threatening, and fatal cases of diarrhea can occur despite loperamide prophylaxis. The risk of severe and life threatening diarrhea is higher when ZIIHERA is administered with chemotherapy and tislelizumab-jsgr, with a higher risk in patients aged ≥ 65 years compared to younger patients.
当ZIIHERA与含氟嘧啶和铂类的化疗药物联合使用,无论是否同时使用替雷利珠单抗-jsgr时,即使采取了洛哌丁胺预防措施,仍可能发生严重、危及生命甚至致命的腹泻病例。当ZIIHERA与化疗药物及替雷利珠单抗-jsgr联合使用时,发生严重且危及生命的腹泻的风险更高,且65岁及以上患者相较于年轻患者风险更高。
Advise patients to increase oral fluids, begin antidiarrheals, and notify their healthcare provider immediately if diarrhea occurs.
建议患者增加口服补液,开始服用止泻药,并在出现腹泻时立即通知其医疗保健提供者。
.
。
Administer antidiarrheal prophylaxis with loperamide in cycle 1 for all patients receiving ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy with or without tislelizumab-jsgr. Begin loperamide at the first loose stool when ZIIHERA is administered in combination with chemotherapy.
在所有接受 ZIIHERA 联合含氟嘧啶和铂类化疗(伴或不伴替雷利珠单抗-jsgr)治疗的患者中,于第 1 个周期给予洛哌丁胺进行腹泻预防。当 ZIIHERA 与化疗联合给药时,一旦出现首次稀便即开始服用洛哌丁胺。
Administer fluids, electrolytes, and additional antidiarrheal agents as necessary. Before modifying the dose of ZIIHERA, evaluate, modify or discontinue drug(s) contributing to diarrhea in accordance with their respective prescribing information. Withhold, reduce the dose, or permanently discontinue ZIIHERA based on severity..
根据需要给予补液、电解质及额外的止泻药物。在调整 ZIIHERA 剂量之前,应根据各相关药物的处方信息,评估、调整或停用导致腹泻的药物。根据严重程度,暂停给药、降低剂量或永久停用 ZIIHERA。
If treating patients with ZIIHERA in combination with FOLFOX, do not administer the fluorouracil bolus.
若将ZIIHERA与FOLFOX联合用于患者治疗,请勿推注氟尿嘧啶。
ZIIHERA in combination with chemotherapy and tislelizumab-jsgr
ZIIHERA 联合化疗及替雷利珠单抗-jsgr
Diarrhea was reported in 85% of 330 patients in clinical studies, including Grade 4 (2.1%), Grade 3 (24%), and Grade 2 (31%) events. Fatal outcomes resulting from diarrhea occurred in 1.5% of patients. Diarrhea leading to dose reduction of ZIIHERA occurred in 10% of patients, and permanent discontinuation of ZIIHERA occurred in 3.9% of patients..
在临床研究中,330名患者中有85%报告了腹泻,包括4级(2.1%)、3级(24%)和2级(31%)事件。因腹泻导致的死亡结果发生在1.5%的患者中。导致ZIIHERA剂量减少的腹泻发生在10%的患者中,而永久停用ZIIHERA的情况发生在3.9%的患者中。
In cycle 1, diarrhea at Grade 4 severity occurred in 1.5% and Grade 3 severity occurred in 15% of patients despite use of loperamide prophylaxis. The median time to onset for cycle 1 diarrhea was 6 days and median time to resolution was 18 days.
在第1个周期中,尽管使用了洛哌丁胺进行预防,仍有1.5%的患者发生4级严重腹泻,15%的患者发生3级严重腹泻。第1个周期腹泻的中位起病时间为6天,中位缓解时间为18天。
ZIIHERA in combination with chemotherapy
ZIIHERA 联合化疗
Diarrhea was reported in 81% of 395 patients in clinical studies, including Grade 4 (1.3%), Grade 3 (20%) and Grade 2 (33%). Diarrhea leading to dose reduction of ZIIHERA occurred in 10% of patients, and permanent discontinuation of ZIIHERA occurred in 1.8% of patients.
在临床研究的395例患者中,81%报告了腹泻,包括4级(1.3%)、3级(20%)和2级(33%)。10%的患者因腹泻导致ZIIHERA剂量减少,1.8%的患者因腹泻永久停用ZIIHERA。
In cycle 1, diarrhea at Grade 4 severity occurred in 0.8% and Grade 3 severity occurred in 14% of patients despite use of loperamide prophylaxis. The median time to onset for cycle 1 diarrhea was 6 days and median time to resolution was 18 days.
在第1个周期中,尽管使用了洛哌丁胺进行预防,仍有0.8%的患者发生4级严重腹泻,14%的患者发生3级严重腹泻。第1个周期腹泻的中位 onset 时间为6天,中位缓解时间为18天。
Embryo-Fetal Toxicity:
胚胎-胎儿毒性:
Based on the mechanism of action, ZIIHERA can cause fetal harm when administered to a pregnant woman. There are no human or animal data on the use of ZIIHERA in pregnancy. In literature reports, use of a HER2-directed antibody during pregnancy resulted in cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death..
基于作用机制,ZIIHERA 在用于孕妇时可能导致胎儿伤害。目前尚无关于妊娠期使用 ZIIHERA 的人体或动物数据。文献报道显示,妊娠期使用 HER2 靶向抗体可导致羊水过少及羊水过少序列征,表现为肺发育不全、骨骼异常和新生儿死亡。
Verify the pregnancy status of females of reproductive potential prior to the initiation of ZIIHERA. Advise pregnant women and females of reproductive potential that exposure to ZIIHERA during pregnancy or within 4 months prior to conception can result in fetal harm. Advise females of reproductive potential to use effective contraception while receiving ZIIHERA and for 4 months following the last dose of ZIIHERA..
在开始使用ZIIHERA之前,验证具有生育潜力的女性的妊娠状态。告知孕妇及具有生育潜力的女性,在妊娠期间或受孕前4个月内暴露于ZIIHERA可能导致胎儿损害。建议具有生育潜力的女性在接受ZIIHERA治疗期间以及最后一次给药后的4个月内采取有效的避孕措施。
Left Ventricular Dysfunction (LVD):
左心室功能障碍(LVD):
ZIIHERA can cause decreases in left ventricular ejection fraction (LVEF).
ZIIHERA 可导致左心室射血分数(LVEF)降低。
Assess LVEF prior to initiation of ZIIHERA and at regular intervals during treatment. Withhold dose or permanently discontinue ZIIHERA based on severity of adverse reactions.
在开始使用ZIIHERA之前评估左心室射血分数(LVEF),并在治疗期间定期进行评估。根据不良反应的严重程度,暂停给药或永久停用ZIIHERA。
The safety of ZIIHERA has not been established in patients with a baseline ejection fraction that is < 50%.
在基线射血分数低于50%的患者中,ZIIHERA的安全性尚未确立。
ZIIHERA in combination with chemotherapy and tislelizumab-jsgr
ZIIHERA 联合化疗及替雷利珠单抗-jsgr
LVEF decrease (an absolute decline in LVEF of > 10%, resulting in a final value of < 50%) was observed in 9% of 330 patients in clinical studies. LVD leading to permanent discontinuation of ZIIHERA was reported in 3% of patients. Fatal outcomes due to LVD occurred in one patient (0.3%). The median time to first occurrence of LVD was 6.9 months (range: 1.2 to 29.1 months).
在临床研究中,330名患者中有9%观察到左心室射血分数(LVEF)降低(LVEF绝对下降>10%,且最终值<50%)。3%的患者报告了导致永久停用ZIIHERA的左心室功能障碍(LVD)。1名患者(0.3%)发生了因LVD导致的死亡结局。首次发生LVD的中位时间为6.9个月(范围:1.2至29.1个月)。
LVD resolved in 78% of patients..
78%的患者左心室功能障碍得到缓解。
ZIIHERA in combination with chemotherapy
ZIIHERA 联合化疗
LVEF decrease was observed in 5% of 395 patients. LVD leading to permanent discontinuation of ZIIHERA was reported in 1.0% of patients. The median time to first occurrence of LVD was 6.0 months (range: 1.4 to 15.0 months). LVD dysfunction resolved in 70% of patients. Infusion-Related Reactions: ZIIHERA can cause infusion-related reactions (IRRs)..
在395名患者中,有5%观察到左心室射血分数(LVEF)下降。1.0%的患者报告了导致永久停用ZIIHERA的左心室功能障碍(LVD)。首次发生LVD的中位时间为6.0个月(范围:1.4至15.0个月)。70%患者的LVD得到缓解。输液相关反应:ZIIHERA可引起输液相关反应(IRRs)。
Prior to each dose of ZIIHERA, administer premedication to prevent potential IRRs. Monitor patients for signs and symptoms of IRR during ZIIHERA administration and as clinically indicated after completion of infusion. Have medications and emergency equipment to treat IRRs available for immediate use..
在每次给予ZIIHERA之前,应给予预处理药物以预防潜在的输液相关反应(IRR)。在ZIIHERA给药期间以及输注完成后根据临床指征,监测患者是否出现输液相关反应的体征和症状。备妥用于治疗输液相关反应的药物和急救设备,以便立即使用。
If an IRR occurs, slow or stop the infusion, and administer appropriate medical management. Monitor patients until complete resolution of signs and symptoms before resuming. Permanently discontinue ZIIHERA in patients with recurrent severe or life-threatening IRRs.
如果发生输液反应,应减慢或停止输注,并给予适当的医疗处理。在体征和症状完全消退之前持续监测患者,之后方可恢复输注。对于复发性严重或危及生命的输液反应患者,应永久停用ZIIHERA。
ZIIHERA in combination with chemotherapy and tislelizumab-jsgr
ZIIHERA 联合化疗及替雷利珠单抗-jsgr
An IRR was reported in 22% of 330 patients in clinical studies, including Grade 4 (0.3%), Grade 3 (1.2%), and Grade 2 (16%) despite use of prophylaxis. IRRs leading to permanent discontinuation of ZIIHERA were reported in 0.3% of patients. IRRs occurred on the first day of dosing in 17% of patients.
在临床研究中,尽管采取了预防措施,仍有22%的患者(共330例)报告了输液相关反应(IRR),包括4级(0.3%)、3级(1.2%)和2级(16%)。导致永久停用ZIIHERA的IRR发生率为0.3%。17%的患者在首次给药当天发生了IRR。
Of all patients who experienced IRRs, 60% of reactions resolved within the first day..
在所有经历输液相关反应(IRR)的患者中,60%的反应在第一天内得到缓解。
ZIIHERA in combination with chemotherapy
ZIIHERA 联合化疗
An IRR was reported in 24% of 395 patients in clinical studies, including Grade 4 (0.3%), Grade 3 (1.5%), and Grade 2 (18%) despite use of prophylaxis. IRRs leading to permanent discontinuation of ZIIHERA were reported in 1.3% of patients. IRRs occurred on the first day of dosing in 22% of patients.
在临床研究中,尽管采取了预防措施,仍有24%的患者(共395例)报告了输液相关反应(IRR),包括4级(0.3%)、3级(1.5%)和2级(18%)。1.3%的患者因IRR而永久停用ZIIHERA。22%的患者的IRR发生在给药首日。
Of all patients who experienced IRRs, 83% of reactions resolved within the first day..
在所有发生输液相关反应(IRR)的患者中,83%的反应在第一天内消退。
Adverse Reactions
不良反应
ZIIHERA in combination with chemotherapy and tislelizumab-jsgr
ZIIHERA 联合化疗及替雷利珠单抗-jsgr
Serious adverse reactions occurred in 59% of 294 patients in HERIZON-GEA-01. Serious adverse reactions in > 2% of patients included diarrhea (17%), IRR (5%), vomiting (4.8%), hypokalemia (4.4%), acute kidney injury (3.7%), pneumonia (3.7%), nausea (2.4%), decreased appetite (2.4%), and anemia (2.4%).
在HERIZON-GEA-01研究的294例患者中,59%发生了严重不良反应。发生率超过2%的严重不良反应包括:腹泻(17%)、输液相关反应(5%)、呕吐(4.8%)、低钾血症(4.4%)、急性肾损伤(3.7%)、肺炎(3.7%)、恶心(2.4%)、食欲减退(2.4%)和贫血(2.4%)。
Fatal adverse reactions occurred in 2.4% of patients and included acute kidney injury (N=2), cardiac failure, diarrhea, dehydration, hypovolemic shock and intestinal obstruction (all N=1)..
2.4%的患者发生了致命性不良反应,包括急性肾损伤(N=2)、心力衰竭、腹泻、脱水、低血容量性休克和肠梗阻(均为N=1)。
Permanent discontinuation of ZIIHERA occurred in 13% of patients. Adverse reactions that resulted in permanent discontinuation of ZIIHERA in ≥ 1% of patients included diarrhea (4.4%) and ejection fraction decreased (2.7%).
13%的患者永久停用ZIIHERA。导致≥1%患者永久停用ZIIHERA的不良反应包括腹泻(4.4%)和射血分数降低(2.7%)。
The most common adverse reactions (≥ 20%) were diarrhea (83%), nausea (56%), decreased appetite (46%), vomiting (44%), hypokalemia (39%), fatigue (37%), rash (36%), peripheral neuropathy (27%), and IRR (25%).
最常见的不良反应(≥20%)包括腹泻(83%)、恶心(56%)、食欲减退(46%)、呕吐(44%)、低钾血症(39%)、疲劳(37%)、皮疹(36%)、周围神经病变(27%)和输液相关反应(25%)。
ZIIHERA in combination with chemotherapy
ZIIHERA 联合化疗
Serious adverse reactions occurred in 49% of 305 patients in HERIZON-GEA-01. Serious adverse reactions in > 2% of patients included diarrhea (11%), vomiting (3.3%), decreased appetite (2.6%), pneumonia (2.6%), sepsis (2.6%), hypokalemia (2.3%), and nausea (2.3%).
在 HERIZON-GEA-01 研究的 305 名患者中,49% 发生了严重不良反应。发生率大于 2% 的严重不良反应包括腹泻(11%)、呕吐(3.3%)、食欲减退(2.6%)、肺炎(2.6%)、败血症(2.6%)、低钾血症(2.3%)和恶心(2.3%)。
Permanent discontinuation of ZIIHERA occurred in 10% of patients. Adverse reactions that resulted in permanent discontinuation of ZIIHERA in ≥ 1% of patients included ejection fraction decreased (2.0%), IRR (1.6%), and diarrhea (1.6%).
10%的患者永久停用ZIIHERA。导致≥1%患者永久停用ZIIHERA的不良反应包括射血分数降低(2.0%)、输液相关反应(1.6%)和腹泻(1.6%)。
The most common adverse reactions (≥ 20%) were diarrhea (79%), nausea (54%), vomiting (44%), decreased appetite (40%), fatigue (36%), hypokalemia (33%), peripheral neuropathy (32%), IRR (25%), and rash (22%).
最常见的不良反应(≥ 20%)为腹泻(79%)、恶心(54%)、呕吐(44%)、食欲减退(40%)、疲劳(36%)、低钾血症(33%)、周围神经病变(32%)、输注相关反应(25%)和皮疹(22%)。
Pediatric Use:
儿童用药:
Safety and efficacy of ZIIHERA have not been established in pediatric patients.
ZIIHERA 在儿科患者中的安全性和有效性尚未确立。
Geriatric Use
老年用药
ZIIHERA in combination with chemotherapy and tislelizumab-jsgr
ZIIHERA 联合化疗及替雷利珠单抗-jsgr
Of 302 patients randomized to ZIIHERA in combination with chemotherapy and tislelizumab-jsgr in HERIZON-GEA-01, there were 139 (46%) patients aged ≥ 65 years. One hundred and six (35%) were aged 65-74 years and 33 (11%) were aged ≥ 75 years.
在HERIZON-GEA-01研究中,302例随机接受ZIIHERA联合化疗及替雷利珠单抗-jsgr治疗的患者中,有139例(46%)年龄≥65岁。其中,106例(35%)年龄为65-74岁,33例(11%)年龄≥75岁。
There was a higher incidence of Grade ≥ 3 adverse reactions observed in patients aged ≥ 65 years (87%) as compared to younger patients (80%). The incidence of Grade 3 or 4 diarrhea was higher in patients aged ≥ 65 years (32%) compared to younger patients (20%).
在≥65岁的患者中,观察到≥3级不良反应的发生率(87%)高于年轻患者(80%)。≥65岁患者的3级或4级腹泻发生率(32%)也高于年轻患者(20%)。
There was an increased incidence of fatal adverse reactions in patients aged ≥ 65 years (4.4%); including acute kidney injury (N=2), cardiac failure, dehydration, hypovolemic shock and intestinal obstruction (all N=1), compared to younger patients (0.6%), including diarrhea (N=1).
与较年轻患者(0.6%,包括1例腹泻)相比,年龄≥65岁的患者致命性不良反应发生率更高(4.4%),包括急性肾损伤(N=2)、心力衰竭、脱水、低血容量性休克和肠梗阻(均为N=1)。
ZIIHERA in combination with chemotherapy
ZIIHERA 联合化疗
Of 304 patients randomized to ZIIHERA in combination with chemotherapy in HERIZON-GEA-01, there were 130 (43%) patients aged ≥ 65 years. One hundred (33%) were aged 65-74 years and 30 (10%) were aged ≥ 75 years.
在HERIZON-GEA-01研究中,304名随机接受ZIIHERA联合化疗的患者中,有130名(43%)患者年龄≥65岁。其中,100名(33%)患者年龄在65-74岁之间,30名(10%)患者年龄≥75岁。
No overall differences in safety were observed between patients aged ≥ 65 years and younger adult patients.
在≥65岁患者与较年轻成年患者之间,未观察到安全性方面的总体差异。
® TEVIMBRA (tislelizumab) is a registered trademark of BeOne Medicines.
® TEVIMBRA(替雷利珠单抗)是百奥泰医药的注册商标。
About
关于
Jazz Pharmaceuticals
爵士制药
Jazz Pharmaceuticals plc (Nasdaq:
Jazz Pharmaceuticals plc(纳斯达克:
JAZZ
爵士乐
) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders.
)是一家全球性生物制药公司,其宗旨是通过创新改变患者及其家人的生活。我们致力于为罕见病患者开发具有变革意义的药物,这些患者往往面临治疗选择有限甚至无药可治的困境。我们拥有多元化的产品组合,包括针对癫痫、癌症和睡眠障碍的领先疗法。
Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide.
我们以患者为中心、以科学为驱动的方法,推动了我们在丰富创新疗法管线中前沿的研发进展。Jazz 总部位于爱尔兰都柏林,在多个国家设有研发实验室、生产设施并拥有员工,致力于服务全球患者。
Please visit .
请访问。
www.jazzpharmaceuticals.com
www.jazzpharmaceuticals.com
for more information.
欲了解更多信息。
Cautionary Note Concerning Forward-Looking Statements
关于前瞻性陈述的警示说明
This press release contains forward-looking statements, including, but not limited to, statements related to the potential therapeutic and differentiated clinical benefits of Ziihera and of combination therapies with Ziihera, including Ziihera's potential to extend survival, Ziihera's potential as a new standard of care in HER2+ first-line GEA and other HER2-expressing cancers and other statements that are not historical facts.
本新闻稿包含前瞻性陈述,包括但不限于与Ziihera的潜在治疗作用和差异化临床益处、以及含Ziihera的联合疗法的潜在治疗作用和差异化临床益处相关的陈述,包括Ziihera延长生存期的潜力、Ziihera作为HER2阳性一线胃食管腺癌(GEA)及其他表达HER2的癌症新标准治疗方案的潜力,以及其他非历史事实的陈述。
These forward-looking statements are based on Jazz Pharmaceuticals' current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the successful completion of regulatory activities and uncertain regulatory approval, risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients and other risks and uncertainties affecting Jazz Pharmaceuticals and its development programs, including those described from time to time under the caption 'Risk Factors' and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission filings and reports, including Jazz Pharmaceuticals' Annual Report on Form 10-K for the year ended December 31, 2025 and future filings and reports by Jazz Pharmaceuticals.
这些前瞻性陈述基于Jazz Pharmaceuticals当前的计划、目标、估计、预期和意图,并 inherently 涉及重大风险和不确定性。由于这些风险和不确定性,实际结果和事件发生的时间可能与上述前瞻性陈述中的预期存在重大差异。这些风险和不确定性包括但不限于:与监管活动的顺利完成及监管审批的不确定性相关的风险和不确定性;与未能或延迟成功启动或完成临床试验以及患者评估相关的风险;以及影响Jazz Pharmaceuticals及其开发项目的其他风险和不确定性,包括在Jazz Pharmaceuticals向美国证券交易委员会(SEC)提交的文件和报告中“风险因素”标题下不时描述的内容,以及其他部分所述的风险和不确定性,其中包括Jazz Pharmaceuticals截至2025年12月31日的年度10-K表报告以及未来由Jazz Pharmaceuticals提交的文件和报告。
Other risks and uncertainties of which Jazz Pharmaceuticals is not currently aware may also affect Jazz Pharmaceuticals' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the da.
Jazz Pharmaceuticals 目前尚未知悉的其他风险和不确定性也可能影响其前瞻性陈述,并可能导致实际结果和事件发生时间与预期存在重大差异。本文中的前瞻性陈述仅截至作出之日有效。
Contacts:
联系人:
Media:
媒体:
[email protected]
[email protected]
Ireland +353 1 637 2141
爱尔兰 +353 1 637 2141
U.S. +1 215 867 4948
美国 +1 215 867 4948
Investor:
投资者:
[email protected]
[email protected]
Ireland +353 1 634 7800
爱尔兰 +353 1 634 7800
U.S. +1 650 496 2717
美国 +1 650 496 2717
1
1
Bray F., et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024 April; doi.org/10.3322/caac.21834Digital Object Identifier (DOI).
Bray F. 等。《2022年全球癌症统计:185个国家36种癌症的全球发病率和死亡率GLOBOCAN估算》。《临床医师癌症杂志》(CA: A Cancer Journal for Clinicians)。2024年4月;doi.org/10.3322/caac.21834 数字对象标识符(DOI)。
2
2
Abrahao-Machado I.F., et al. HER2 testing in gastric cancer: An update WorldJGastroenterol. 2016;22(19):4619-4625.
Abrahao-Machado I.F. 等. 胃癌中的 HER2 检测:最新进展. 《世界胃肠病学杂志》. 2016;22(19):4619-4625.
3
3
Van Custem E., et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476-484.
Van Custem E. 等。来自 ToGA 研究的 HER2 筛查数据:靶向胃癌及胃食管结合部癌中的 HER2。《胃癌》。2015;18(3):476-484。
4
4
Stroes, C.I., et al. A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: Successes achieved and opportunities ahead. CancerTreatRev. 2021;99:102249.
Stroes, C.I., 等. HER2阻断用于胃食管腺癌根治性治疗的系统评价:已取得的成就与未来的机遇. Cancer Treat Rev. 2021;99:102249.
5
5
Tabernero J., et al. HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Taylor & Francis. 2022 July; doi.org/10.2217/fon-2022-0595.
Tabernero J. 等. HERIZON-GEA-01:Zanidatamab + 化疗 ± tislelizumab 用于 HER2 阳性胃食管腺癌的一线治疗。Taylor & Francis. 2022年7月;doi.org/10.2217/fon-2022-0595.
6
6
ZIIHERA (zanidatamab-hrii) Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc.
ZIIHERA(zanidatamab-hrii)处方信息。加利福尼亚州帕洛阿尔托:Jazz Pharmaceuticals, Inc.
SOURCE Jazz Pharmaceuticals plc
来源:Jazz Pharmaceuticals plc
21
二十一
%
%
more press release views with
更多新闻稿浏览量,通过
Request a Demo
申请演示